Skip to main content
Erschienen in: Cancer Causes & Control 2/2016

01.02.2016 | Original paper

Use of exogenous hormones and the risk of breast cancer: results from self-reported survey data with validity assessment

verfasst von: Sanna Heikkinen, Markku Koskenvuo, Nea Malila, Tytti Sarkeala, Eero Pukkala, Janne Pitkäniemi

Erschienen in: Cancer Causes & Control | Ausgabe 2/2016

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Main aim was to estimate the association between use of exogenous hormones and breast cancer (BC) risk in a large population-based survey, and to assess the representativeness and overall validity of the data.

Methods

The survey ‘Women’s Health and Use of Hormones’ was conducted in Finland in 2009, including 7,000 BC cases and 20,000 matched population controls. Conditional logistic regression was used to estimate odds ratios and their 95 % confidence interval. For validation, exposure prevalences were compared with population data from Statistics Finland and two large population-based surveys.

Results

We found positive associations with BC risk and exclusive use of hormone-releasing intrauterine device (HR IUD) in postmenopausal women (1.48, 95 % CI 1.10–1.99), when compared to never-users of any hormonal contraceptive and considering only prediagnostic use in cases. Regarding use of other hormonal contraceptives (HC), a positive association between long HC use (≥2 years) and BC was observed in both groups, OR being 1.37 (95 % CI 1.12–1.68) for premenopausal and 1.11 (95 % CI 1.03–1.20) for postmenopausal women, when compared to never-users of other HC.

Conclusions

Observed association between HR IUD use and risk of BC in postmenopausal women is worrying and deserves further attention. Selection bias seemed not to explain this result. Considering the increasing popularity of HR IUD use in, e.g., USA, impact of possible adverse effects in public health could be significant.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
2.
Zurück zum Zitat Engholm G, Ferlay J, Christensen N, Johannesen TB, Khan S, Køtlum JE et al (2013) NORDCAN: cancer incidence, mortality, prevalence and survival in the nordic countries, version 6.0 (4 Dec 2013). http://www-dep.iarc.fr/nordcan.htm. Accessed 4 Dec 2014 Engholm G, Ferlay J, Christensen N, Johannesen TB, Khan S, Køtlum JE et al (2013) NORDCAN: cancer incidence, mortality, prevalence and survival in the nordic countries, version 6.0 (4 Dec 2013). http://​www-dep.​iarc.​fr/​nordcan.​htm. Accessed 4 Dec 2014
4.
Zurück zum Zitat Collaborative Group on Hormonal Factors in Breast Cancer (2001) Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease. Lancet 358(9291):1389–1399CrossRef Collaborative Group on Hormonal Factors in Breast Cancer (2001) Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease. Lancet 358(9291):1389–1399CrossRef
5.
Zurück zum Zitat Hartmann LC, Sellers TA, Frost MH, Lingle WL, Degnim AC, Ghosh K et al (2005) Benign breast disease and the risk of breast cancer. N Engl J Med 353(3):229–237PubMedCrossRef Hartmann LC, Sellers TA, Frost MH, Lingle WL, Degnim AC, Ghosh K et al (2005) Benign breast disease and the risk of breast cancer. N Engl J Med 353(3):229–237PubMedCrossRef
6.
Zurück zum Zitat McCormack VA, dos Santos Silva I (2006) Breast density and parenchymal patterns as markers of breast cancer risk: a meta-analysis. Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol 15(6):1159–1169CrossRef McCormack VA, dos Santos Silva I (2006) Breast density and parenchymal patterns as markers of breast cancer risk: a meta-analysis. Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol 15(6):1159–1169CrossRef
7.
Zurück zum Zitat Folkerd E, Dowsett M (2013) Sex hormones and breast cancer risk and prognosis. Breast 22:S38–S43PubMedCrossRef Folkerd E, Dowsett M (2013) Sex hormones and breast cancer risk and prognosis. Breast 22:S38–S43PubMedCrossRef
8.
Zurück zum Zitat Collaborative Group on Hormonal Factors in Breast Cancer (2012) Menarche, menopause, and breast cancer risk: individual participant meta-analysis, including 118 964 women with breast cancer from 117 epidemiological studies. Lancet Oncol 13(11):1141–1151PubMedCentralCrossRef Collaborative Group on Hormonal Factors in Breast Cancer (2012) Menarche, menopause, and breast cancer risk: individual participant meta-analysis, including 118 964 women with breast cancer from 117 epidemiological studies. Lancet Oncol 13(11):1141–1151PubMedCentralCrossRef
9.
Zurück zum Zitat Kobayashi S, Sugiura H, Ando Y, Shiraki N, Yanagi T, Yamashita H et al (2012) Reproductive history and breast cancer risk. Breast Cancer 19(4):302–308PubMedPubMedCentralCrossRef Kobayashi S, Sugiura H, Ando Y, Shiraki N, Yanagi T, Yamashita H et al (2012) Reproductive history and breast cancer risk. Breast Cancer 19(4):302–308PubMedPubMedCentralCrossRef
10.
Zurück zum Zitat Anderson KN, Schwab RB, Martinez ME (2014) Reproductive risk factors and breast cancer subtypes: a review of the literature. Breast Cancer Res Treat 144(1):1–10PubMedPubMedCentralCrossRef Anderson KN, Schwab RB, Martinez ME (2014) Reproductive risk factors and breast cancer subtypes: a review of the literature. Breast Cancer Res Treat 144(1):1–10PubMedPubMedCentralCrossRef
12.
Zurück zum Zitat Hunter DJ, Colditz GA, Hankinson SE, Malspeis S, Spiegelman D, Chen W et al (2010) Oral contraceptive use and breast cancer: a prospective study of young women. Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol 19(10):2496–2502CrossRef Hunter DJ, Colditz GA, Hankinson SE, Malspeis S, Spiegelman D, Chen W et al (2010) Oral contraceptive use and breast cancer: a prospective study of young women. Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol 19(10):2496–2502CrossRef
13.
Zurück zum Zitat Rosenberg L, Zhang Y, Coogan PF, Strom BL, Palmer JR (2009) A case–control study of oral contraceptive use and incident breast cancer. Am J Epidemiol 169(4):473–479PubMedPubMedCentralCrossRef Rosenberg L, Zhang Y, Coogan PF, Strom BL, Palmer JR (2009) A case–control study of oral contraceptive use and incident breast cancer. Am J Epidemiol 169(4):473–479PubMedPubMedCentralCrossRef
14.
Zurück zum Zitat Marchbanks PA, Curtis KM, Mandel MG, Wilson HG, Jeng G, Folger SG et al (2012) Oral contraceptive formulation and risk of breast cancer. Contraception 85(4):342–350PubMedPubMedCentralCrossRef Marchbanks PA, Curtis KM, Mandel MG, Wilson HG, Jeng G, Folger SG et al (2012) Oral contraceptive formulation and risk of breast cancer. Contraception 85(4):342–350PubMedPubMedCentralCrossRef
15.
Zurück zum Zitat Lyytinen HK, Dyba T, Ylikorkala O, Pukkala EI (2010) A case–control study on hormone therapy as a risk factor for breast cancer in Finland: intrauterine system carries a risk as well. Int J Cancer J Int Cancer 126(2):483–489CrossRef Lyytinen HK, Dyba T, Ylikorkala O, Pukkala EI (2010) A case–control study on hormone therapy as a risk factor for breast cancer in Finland: intrauterine system carries a risk as well. Int J Cancer J Int Cancer 126(2):483–489CrossRef
16.
Zurück zum Zitat Soini T, Hurskainen R, Grénman S, Mäenpää J, Paavonen J, Pukkala E (2014) Cancer risk in women using the levonorgestrel-releasing intrauterine system in Finland. Obstet Gynecol 124(2 Pt 1):292–299PubMedCrossRef Soini T, Hurskainen R, Grénman S, Mäenpää J, Paavonen J, Pukkala E (2014) Cancer risk in women using the levonorgestrel-releasing intrauterine system in Finland. Obstet Gynecol 124(2 Pt 1):292–299PubMedCrossRef
17.
Zurück zum Zitat Dinger J, Bardenheuer K, Minh TD (2011) Levonorgestrel-releasing and copper intrauterine devices and the risk of breast cancer. Contraception 83(3):211–217PubMedCrossRef Dinger J, Bardenheuer K, Minh TD (2011) Levonorgestrel-releasing and copper intrauterine devices and the risk of breast cancer. Contraception 83(3):211–217PubMedCrossRef
18.
Zurück zum Zitat Backman T, Rauramo I, Jaakkola K, Inki P, Vaahtera K, Launonen A et al (2005) Use of the levonorgestrel-releasing intrauterine system and breast cancer. Obstet Gynecol 106(4):813–817PubMedCrossRef Backman T, Rauramo I, Jaakkola K, Inki P, Vaahtera K, Launonen A et al (2005) Use of the levonorgestrel-releasing intrauterine system and breast cancer. Obstet Gynecol 106(4):813–817PubMedCrossRef
19.
Zurück zum Zitat Beral V, Million Women Study Collaborators (2003) Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet Lond Engl 362(9382):419–427CrossRef Beral V, Million Women Study Collaborators (2003) Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet Lond Engl 362(9382):419–427CrossRef
20.
Zurück zum Zitat Hou N, Hong S, Wang W, Olopade OI, Dignam JJ, Huo D (2013) Hormone replacement therapy and breast cancer: heterogeneous risks by race, weight, and breast density. J Natl Cancer Inst 105(18):1365–1372PubMedPubMedCentralCrossRef Hou N, Hong S, Wang W, Olopade OI, Dignam JJ, Huo D (2013) Hormone replacement therapy and breast cancer: heterogeneous risks by race, weight, and breast density. J Natl Cancer Inst 105(18):1365–1372PubMedPubMedCentralCrossRef
21.
Zurück zum Zitat Lee SA, Ross RK, Pike MC (2005) An overview of menopausal oestrogen-progestin hormone therapy and breast cancer risk. Br J Cancer 92(11):2049–2058PubMedPubMedCentralCrossRef Lee SA, Ross RK, Pike MC (2005) An overview of menopausal oestrogen-progestin hormone therapy and breast cancer risk. Br J Cancer 92(11):2049–2058PubMedPubMedCentralCrossRef
22.
Zurück zum Zitat Collins JA, Blake JM, Crosignani PG (2005) Breast cancer risk with postmenopausal hormonal treatment. Hum Reprod Update 11(6):545–560PubMedCrossRef Collins JA, Blake JM, Crosignani PG (2005) Breast cancer risk with postmenopausal hormonal treatment. Hum Reprod Update 11(6):545–560PubMedCrossRef
23.
Zurück zum Zitat Rothman KJ, Greenland S, Lash TR (2008) Modern epidemiology, 3rd edn. Lippincott Williams & Wilkins, Philadelphia Rothman KJ, Greenland S, Lash TR (2008) Modern epidemiology, 3rd edn. Lippincott Williams & Wilkins, Philadelphia
24.
Zurück zum Zitat Peytcheva E, Groves RM (2009) Using variation in response rates of demographic subgroups as evidence of nonresponse bias in survey estimates. J Off Stat 25(2):193–201 Peytcheva E, Groves RM (2009) Using variation in response rates of demographic subgroups as evidence of nonresponse bias in survey estimates. J Off Stat 25(2):193–201
25.
Zurück zum Zitat Etter JF, Perneger TV (1997) Analysis of non-response bias in a mailed health survey. J Clin Epidemiol 50(10):1123–1128PubMedCrossRef Etter JF, Perneger TV (1997) Analysis of non-response bias in a mailed health survey. J Clin Epidemiol 50(10):1123–1128PubMedCrossRef
26.
Zurück zum Zitat Groves RM, Peytcheva E (2008) The impact of nonresponse rates on nonresponse bias: a meta-analysis. Public Opin Q 72:167–189CrossRef Groves RM, Peytcheva E (2008) The impact of nonresponse rates on nonresponse bias: a meta-analysis. Public Opin Q 72:167–189CrossRef
27.
Zurück zum Zitat Teppo L, Pukkala E, Lehtonen M (1994) Data quality and quality control of a population-based cancer registry. Experience in Finland. Acta Oncol Stockh Swed 33(4):365–369CrossRef Teppo L, Pukkala E, Lehtonen M (1994) Data quality and quality control of a population-based cancer registry. Experience in Finland. Acta Oncol Stockh Swed 33(4):365–369CrossRef
31.
Zurück zum Zitat Nelson HD, Zakher B, Cantor A, Fu R, Griffin J, O’Meara ES et al (2012) Risk factors for breast cancer for women aged 40 to 49 years: a systematic review and meta-analysis. Ann Intern Med 156(9):635–648PubMedPubMedCentralCrossRef Nelson HD, Zakher B, Cantor A, Fu R, Griffin J, O’Meara ES et al (2012) Risk factors for breast cancer for women aged 40 to 49 years: a systematic review and meta-analysis. Ann Intern Med 156(9):635–648PubMedPubMedCentralCrossRef
32.
Zurück zum Zitat Hamajima N, Hirose K, Tajima K, Rohan T, Calle EE, Heath CW Jr et al (2002) Alcohol, tobacco and breast cancer–collaborative reanalysis of individual data from 53 epidemiological studies, including 58,515 women with breast cancer and 95,067 women without the disease. Br J Cancer 87(11):1234–1245PubMedCrossRef Hamajima N, Hirose K, Tajima K, Rohan T, Calle EE, Heath CW Jr et al (2002) Alcohol, tobacco and breast cancer–collaborative reanalysis of individual data from 53 epidemiological studies, including 58,515 women with breast cancer and 95,067 women without the disease. Br J Cancer 87(11):1234–1245PubMedCrossRef
33.
Zurück zum Zitat Reeves Gk, Pirie K, Green J, Bull D, Beral V, Million Women Study Collaborators (2012) Comparison of the effects of genetic and environmental risk factors on in situ and invasive ductal breast cancer. Int J Cancer J Int Cancer 131(4):930–937CrossRef Reeves Gk, Pirie K, Green J, Bull D, Beral V, Million Women Study Collaborators (2012) Comparison of the effects of genetic and environmental risk factors on in situ and invasive ductal breast cancer. Int J Cancer J Int Cancer 131(4):930–937CrossRef
34.
Zurück zum Zitat Li H, Beeghly-Fadiel A, Wen W, Lu W, Gao YT, Xiang YB et al (2013) Gene-environment interactions for breast cancer risk among Chinese women: a report from the Shanghai Breast Cancer Genetics Study. Am J Epidemiol 177(2):161–170PubMedPubMedCentralCrossRef Li H, Beeghly-Fadiel A, Wen W, Lu W, Gao YT, Xiang YB et al (2013) Gene-environment interactions for breast cancer risk among Chinese women: a report from the Shanghai Breast Cancer Genetics Study. Am J Epidemiol 177(2):161–170PubMedPubMedCentralCrossRef
35.
Zurück zum Zitat Ghiasvand R, Maram ES, Tahmasebi S, Tabatabaee SHR (2011) Risk factors for breast cancer among young women in southern Iran. Int J Cancer 129(6):1443–1449PubMedCrossRef Ghiasvand R, Maram ES, Tahmasebi S, Tabatabaee SHR (2011) Risk factors for breast cancer among young women in southern Iran. Int J Cancer 129(6):1443–1449PubMedCrossRef
36.
Zurück zum Zitat Kotsopoulos J, Chen WY, Gates MA, Tworoger SS, Hankinson SE, Rosner BA (2010) Risk factors for ductal and lobular breast cancer: results from the nurses’ health study. Breast Cancer Res 12(6):R106PubMedPubMedCentralCrossRef Kotsopoulos J, Chen WY, Gates MA, Tworoger SS, Hankinson SE, Rosner BA (2010) Risk factors for ductal and lobular breast cancer: results from the nurses’ health study. Breast Cancer Res 12(6):R106PubMedPubMedCentralCrossRef
37.
Zurück zum Zitat Lyytinen HK, Dyba T, Ylikorkala O, Pukkala EI (2010) A case–control study on hormone therapy as a risk factor for breast cancer in Finland: intrauterine system carries a risk as well. Int J Cancer J Int Cancer 126(2):483–489CrossRef Lyytinen HK, Dyba T, Ylikorkala O, Pukkala EI (2010) A case–control study on hormone therapy as a risk factor for breast cancer in Finland: intrauterine system carries a risk as well. Int J Cancer J Int Cancer 126(2):483–489CrossRef
38.
Zurück zum Zitat Gierisch JM, Coeytaux RR, Urrutia RP, Havrilesky LJ, Moorman PG, Lowery WJ et al (2013) Oral contraceptive use and risk of breast, cervical, colorectal, and endometrial cancers: a systematic review. Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol 22(11):1931–1943CrossRef Gierisch JM, Coeytaux RR, Urrutia RP, Havrilesky LJ, Moorman PG, Lowery WJ et al (2013) Oral contraceptive use and risk of breast, cervical, colorectal, and endometrial cancers: a systematic review. Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol 22(11):1931–1943CrossRef
39.
Zurück zum Zitat Beaber EF, Buist DSM, Barlow WE, Malone KE, Reed SD, Li CI (2014) Recent oral contraceptive use by formulation and breast cancer risk among women 20 to 49 years of age. Cancer Res 74(15):4078–4089PubMedPubMedCentralCrossRef Beaber EF, Buist DSM, Barlow WE, Malone KE, Reed SD, Li CI (2014) Recent oral contraceptive use by formulation and breast cancer risk among women 20 to 49 years of age. Cancer Res 74(15):4078–4089PubMedPubMedCentralCrossRef
40.
Zurück zum Zitat Vessey M, Yeates D (2013) Oral contraceptive use and cancer: final report from the Oxford-Family Planning Association contraceptive study. Contraception 88(6):678–683PubMedCrossRef Vessey M, Yeates D (2013) Oral contraceptive use and cancer: final report from the Oxford-Family Planning Association contraceptive study. Contraception 88(6):678–683PubMedCrossRef
41.
Zurück zum Zitat Braaten T, Weiderpass E, Kumle M, Adami H-O, Lund E (2004) Education and risk of breast cancer in the Norwegian-Swedish women’s lifestyle and health cohort study. Int J Cancer 110(4):579–583PubMedCrossRef Braaten T, Weiderpass E, Kumle M, Adami H-O, Lund E (2004) Education and risk of breast cancer in the Norwegian-Swedish women’s lifestyle and health cohort study. Int J Cancer 110(4):579–583PubMedCrossRef
42.
Zurück zum Zitat Soini T, Hurskainen R, Grénman S, Mäenpää J, Paavonen J, Joensuu H et al (2015) Levonorgestrel-releasing intrauterine system and the risk of breast cancer: a nationwide cohort study. Acta Oncol Stockh Swed 4:1–5 Soini T, Hurskainen R, Grénman S, Mäenpää J, Paavonen J, Joensuu H et al (2015) Levonorgestrel-releasing intrauterine system and the risk of breast cancer: a nationwide cohort study. Acta Oncol Stockh Swed 4:1–5
43.
Zurück zum Zitat Marchbanks PA, McDonald JA, Wilson HG, Folger SG, Mandel MG, Daling JR et al (2002) Oral contraceptives and the risk of breast cancer. N Engl J Med 346(26):2025–2032PubMedCrossRef Marchbanks PA, McDonald JA, Wilson HG, Folger SG, Mandel MG, Daling JR et al (2002) Oral contraceptives and the risk of breast cancer. N Engl J Med 346(26):2025–2032PubMedCrossRef
45.
46.
Zurück zum Zitat Strandhagen E, Berg C, Lissner L, Nunez L, Rosengren A, Torén K et al (2010) Selection bias in a population survey with registry linkage: potential effect on socioeconomic gradient in cardiovascular risk. Eur J Epidemiol 25(3):163–172PubMedCrossRef Strandhagen E, Berg C, Lissner L, Nunez L, Rosengren A, Torén K et al (2010) Selection bias in a population survey with registry linkage: potential effect on socioeconomic gradient in cardiovascular risk. Eur J Epidemiol 25(3):163–172PubMedCrossRef
47.
Zurück zum Zitat Groves RM, Presser S, Dipko S (2004) The role of topic interest in survey participation decisions. Public Opin Q 68(1):2–31CrossRef Groves RM, Presser S, Dipko S (2004) The role of topic interest in survey participation decisions. Public Opin Q 68(1):2–31CrossRef
Metadaten
Titel
Use of exogenous hormones and the risk of breast cancer: results from self-reported survey data with validity assessment
verfasst von
Sanna Heikkinen
Markku Koskenvuo
Nea Malila
Tytti Sarkeala
Eero Pukkala
Janne Pitkäniemi
Publikationsdatum
01.02.2016
Verlag
Springer International Publishing
Erschienen in
Cancer Causes & Control / Ausgabe 2/2016
Print ISSN: 0957-5243
Elektronische ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-015-0702-5

Weitere Artikel der Ausgabe 2/2016

Cancer Causes & Control 2/2016 Zur Ausgabe

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.